Immunogenicity and efficacy of an mRNA vaccine expressing a virus-like particle spike antigen against SARS-CoV-2

Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Data for studies directly listed on Vivli can be requested through Vivli at www.vivli.org. Data for studies not listed on Vivli could be requested through Vivli at https://vivli.org/members/enquiries-about-studies-not-listed-on-the-vivli-platform/. AstraZeneca Vivli member page is also available outlining further details: https://vivli.org/ourmember/astrazeneca/.

1. Markov, P. V. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21, 361–379 (2023).

   Google Scholar 

2. Yang, Y. et al. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nat. Microbiol. 7, 423–433 (2022).

   Google Scholar 

3. Arunachalam, P. S. et al. Durable protection against the SARS-CoV-2 omicron variant is induced by an adjuvanted subunit vaccine. Sci. Transl. Med. 14, eabq4130 (2022).

   Google Scholar 

4. Tanne, J. H. Covid-19: Pfizer-BioNTech vaccine is rolled out in the US. BMJ 371, m4836 (2020).

   Google Scholar 

5. Schoenmaker, L. et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int. J. Pharm. 601, 120586 (2021).

   Google Scholar 

6. Snapper, C. M. Distinct immunologic properties of soluble versus particulate antigens. Front. Immunol. 9, 598 (2018).

   Google Scholar 

7. Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S. & DeRosa, F. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines 5, 11 (2020).

   Google Scholar 

8. Liu, C. et al. Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery. NPJ Vaccines 8, 111 (2023).

   Google Scholar 

9. Xu, Z. et al. In vivo assembly of nanoparticles achieved through synergy of structure-based protein engineering and synthetic DNA generates enhanced adaptive immunity. Adv. Sci. 7, 1902802 (2020).

   Google Scholar 

10. Kato, Y. et al. Multifaceted effects of antigen valency on B cell response composition and differentiation in vivo. Immunity 53, 548–63.e8 (2020).

    Google Scholar 

11. Patel, K. G. & Swartz, J. R. Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry. Bioconjug. Chem. 22, 376–387 (2011).

    Google Scholar 

12. Grgacic, E. V. L. & Anderson, D. A. Virus-like particles: passport to immune recognition. Methods 40, 60–65 (2006).

    Google Scholar 

13. Roldão, A., Mellado, M. C., Castilho, L. R., Carrondo, M. J. & Alves, P. M. Virus-like particles in vaccine development. Expert Rev. Vaccines 9, 1149–1176 (2010).

    Google Scholar 

14. Reutovich, A. A., Srivastava, A. K., Arosio, P. & Bou-Abdallah, F. Ferritin nanocages as efficient nanocarriers and promising platforms for COVID-19 and other vaccines development. Biochim. Biophys. Acta Gen. Subj. 1867, 130288 (2023).

    Google Scholar 

15. Kanekiyo, M. et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102–106 (2013).

    Google Scholar 

16. Houser, K. V. et al. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat. Med. 28, 383–391 (2022).

    Google Scholar 

17. Widge, A. T. et al. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. Sci. Transl. Med. 15, eade4790 (2023).

    Google Scholar 

18. Ke, Z. et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature 588, 498–502 (2020).

    Google Scholar 

19. Corbett, K. S. et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N. Engl. J. Med. 383, 1544–1555 (2020).

    Google Scholar 

20. Muñoz-Fontela, C. et al. Animal models for COVID-19. Nature 586, 509–515 (2020).

    Google Scholar 

21. Benton, D. J. et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588, 327–330 (2020).

    Google Scholar 

22. Cohen, A. A. et al. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science 377, eabq0839 (2022).

    Google Scholar 

23. Ols, S. et al. Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses. Immunity 56, 2425–41.e14 (2023).

    Google Scholar 

24. Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787–796 (2010).

    Google Scholar 

25. Bachmann, M. F., van Damme, P., Lienert, F. & Schwarz, T. F. Virus-like particles: a versatile and effective vaccine platform. Expert Rev. Vaccines 24, 444–456 (2025).

26. Oyedele, T. et al. editors. Safety and immunogenicity of a SARS-CoV-2 mRNA virus-like particle vaccine in adults 18 years of age and older in a Phase I randomized clinical trial. Proc. Int. Soc. Vaccines 2024, 21–23 (2024).

    Google Scholar 

27. Turoňová, B. et al. In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges. Science 370, 203–208 (2020).

    Google Scholar 

28. Joyce M. G. et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell Rep. 37, 110143.

29. Rosenthal, P. B. & Henderson, R. Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. J. Mol. Biol. 333, 721–745 (2003).

    Google Scholar 

30. Emmaneel, A. et al. PeacoQC: Peak-based selection of high quality cytometry data. Cytom. A 101, 325–338 (2022).

    Google Scholar 

Download references

Author notes

1. Rakesh Choudhary

   Present address: SUNY Upstate Medical University, Syracuse, NY, USA

2. Cheyne Kurokawa, Yueh-Ming Loo & Wade Blair

   Present address: IntegerBio, Gaithersburg, MD, USA

Authors and Affiliations

1. Virology and Vaccine Discovery, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA

   Jason P. Laliberte, Yingyun Cai, Tara Kenny, Yi Zhang, Kuishu Ren, Kim Rosenthal, Daniel Flores, Richard Roque, Vanessa Cadevilla Peano, Noel Janney, Vinita Puri, Sarah Siddiqui, Angela Pack, Giune Padilla, Seme Diallo, Cheyne Kurokawa, Johnathan Guest, Phillip Swanson, Yueh-Ming Loo, Joseph R. Francica, Wade Blair & Mark Esser

2. Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

   Oliver Acton, Yi-Han Cheng & George Thom

3. Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA

   Hibret Adissu, Rakesh Choudhary & Hawley Pruitt

4. Dosage Form Design & Development, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA

   Michael Newton

Contributions

Conceptualization: J.P.L., P.S., Y-M.L., J.R.F., W.B.; Formal analysis: J.P.L., O.A., H.A., P.S., Y-M.L., J.R.F., W.B.; Investigation: J.P.L., Y.C., T.K., Y.Z., K.R., K.R., D.F., R.R., O.A., V.C.P., N.J., V.P., S.S., A.P., G.P., S.D., H.A., R.C., H.P., Y.-H.C., G.T., M.N., C.K., J.G., P.S.; writing—original draft: J.P.L.; writing—review & editing: J.P.L., O.A., H.A., H.P., G.T., P.S., Y.-M.L., J.R.F., W.B., M.E.; visualization: J.P.L., O.A., H.A.; supervision: J.P.L., H.A., G.T., P.S., Y-M.L., J.R.F., W.B., M.E.; funding acquisition: J.P.L., W.B., M.E.

Corresponding author

Correspondence to Jason P. Laliberte.

Competing interests

J.P.L., Y.C., T.K., Y.Z., K.R., K.R., D.F., R.R., O.A., V.C.P., N.J., V.P., S.S., A.P., G.P., S.D., H.A., H.P., Y.-H.C., G.T., M.N., J.G., P.S., J.R.F., M.E. are current employees of AstraZeneca and hold or may hold stock in AstraZeneca. R.C., C.K., Y.-M.L., and W.B. are previous employees of AstraZeneca and hold or may hold stock in AstraZeneca. AstraZeneca has filed patent applications (WO/2024/153794 and US20240277834) related to mRNA-VLP and mRNA vaccines. All other authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions